Seeking Alpha HealthcareOriginal article
AtriCure reiterates 2026 revenue $600M-$610M as BoxX-NoAF enrollment targets year-end completion
Trial StartBoxX-NoAFNeutral
AI Analysis
Summary
AtriCure reiterates its 2026 revenue guidance of $600M-$610M and confirms BoxX-NoAF enrollment is on track for year-end completion.
Clinical Trial Data
Financial Highlights
Revenue
$600M-$610M
Guidance
2026 revenue guidance reiterated at $600M-$610M
Outcome Details
BoxX-NoAF enrollment targeting year-end completion
Importance:5/10
Sentiment:
0.00
guidanceclinical trialrevenue forecast
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on May 6, 2026 6:13 AM